Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 209,097,088
  • Shares Outstanding, K 6,815,420
  • Annual Sales, $ 53,441 M
  • Annual Income, $ 9,723 M
  • 36-Month Beta 0.65
  • Price/Sales N/A
  • Price/Cash Flow 17.66
  • Price/Book 8.44
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/07/18
  • Annual Dividend & Yield 0.85 (2.66%)
  • Most Recent Dividend 0.84 on 03/15/17
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.4500 +0.10%
on 01/17/18
32.4200 -5.98%
on 01/05/18
-0.4200 (-1.36%)
since 12/15/17
3-Month
28.4800 +7.02%
on 11/09/17
32.4200 -5.98%
on 01/05/18
-0.9700 (-3.08%)
since 10/17/17
52-Week
28.4800 +7.02%
on 11/09/17
36.8200 -17.22%
on 04/28/17
+1.0100 (+3.43%)
since 01/17/17

Most Recent Stories

More News
Exelixis, Ipsen Report Positive Results on Lead Cancer Drug

Exelixis (EXEL) and Ipsen announce detailed results from the late stage study of lead drug Cabometyx in patients with previously treated advanced HCC.

EXEL : 27.91 (-5.87%)
RHHBY : 30.4400 (-0.78%)
PFE : 37.02 (+1.15%)
BMY : 60.68 (+1.27%)
Will Amgen (AMGN) Continue to Tread Growth Path This Year?

Amgen (AMGN) stock outperformed the industry in 2017. We will have to wait and see if it can keep the momentum alive in 2018.

AGN : 178.50 (-0.09%)
RHHBY : 30.4400 (-0.78%)
AMGN : 187.20 (+0.89%)
PFE : 37.02 (+1.15%)
Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?

Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.

PBYI : 91.70 (+0.94%)
NVS : 86.70 (-0.03%)
RHHBY : 30.4400 (-0.78%)
GSK : 38.12 (+0.53%)
Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead?

Prothena's (PRTA) stock tumbles more than 18% due to a pipeline setback. The company depends heavily on the success of its two candidates.

ALNY : 125.23 (+0.47%)
EXEL : 27.91 (-5.87%)
PRTA : 40.34 (+0.98%)
RHHBY : 30.4400 (-0.78%)
Roche MS Drug Ocrevus Gets Marketing Authorization in Europe

Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.

EXEL : 27.91 (-5.87%)
RHHBY : 30.4400 (-0.78%)
MKGAF : 112.2000 (+2.56%)
BIIB : 340.91 (+0.61%)
FDA Approvals Surge in 2017: Here's a Look at the Numbers

There was a significant surge in FDA approvals in 2017 with the regulatory body giving its nod to 46 novel drugs plus gene-based therapies like Novartis's (NVS) Kymriah. Here is a closer look at the numbers...

LLY : 85.78 (+0.57%)
GWPH : 130.30 (+1.01%)
NVS : 86.70 (-0.03%)
GILD : 80.95 (+0.87%)
RHHBY : 30.4400 (-0.78%)
REGN : 374.06 (+1.04%)
AMGN : 187.20 (+0.89%)
GE Healthcare Partners Roche for Improved Critical Care

General Electric Company's (GE) segment GE Healthcare will now help to create a digital platform with Roche to advance medicinal treatments particularly for cancer and critical care patients.

RAVN : 36.10 (-0.55%)
RHHBY : 30.4400 (-0.78%)
MMM : 246.82 (+0.85%)
GE : 17.38 (-4.56%)
GE, Roche Enter Partnership to Develop Integrated Digital Diagnostics Platform to Improve Oncology and Critical Care Treatment

--Partnership will apply advanced analytics to in-vivo data from GE's medical imaging and monitoring equipment with in-vitro data from Roche's biomarker, tissue pathology, genomics and sequencing portfolio...

RHHBY : 30.4400 (-0.78%)
GE : 17.38 (-4.56%)
Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial

Exelixis, Inc. (EXEL) announced an amendment to the protocol for the phase Ib trial of cabozantinib combined with Tecentriq whereby there will be four new expansion cohorts to the trial.

EXEL : 27.91 (-5.87%)
RHHBY : 30.4400 (-0.78%)
PFE : 37.02 (+1.15%)
BMY : 60.68 (+1.27%)
ImmunoGen Starts Phase I Study on Leukemia Candidate IMGN632

ImmunoGen (IMGN) begins a phase I study to evaluate its anti-CD123 antibody-drug conjugates, IMGN632, for treating patients with hematological malignancies.

JAZZ : 150.64 (+0.56%)
IMGN : 8.16 (+3.03%)
RHHBY : 30.4400 (-0.78%)
AMGN : 187.20 (+0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Key Turning Points

2nd Resistance Point 30.9633
1st Resistance Point 30.8217
Last Price 30.4450
1st Support Level 30.5067
2nd Support Level 30.3333

See More

52-Week High 36.8200
Fibonacci 61.8% 33.6341
Fibonacci 50% 32.6500
Fibonacci 38.2% 31.6659
Last Price 30.4450
52-Week Low 28.4800

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.